R&D News | pharmaphorum

News

Novo turns to Hengrui for another oral obesity drug

Novo has agreed to pay up to $2.6 billion for rights to a weight-loss pill, developed by China's Hengrui Pharma, that could be dosed just once a week.

News

Mirum puts Hepcludex in its sights with hep D readout

Gilead's Hepcludex was the first drug to be cleared in the US for hepatitis D in May, but a potential rival from Mirum Pharma is already looming.

News

AZ takes stake in Summit Therapeutics in $2bn deal

AstraZeneca has taken a roughly 10% stake in Summit and signed a deal to test CLDN18.2-targeting sone-ve with PD-1xVEGF bispecific ivonescimab.

News

Roche culls myostatin candidate from obesity pipeline

Roche has abandoned the development of one of its obesity candidates, emugrobart, and returned rights to originator Chugai Pharma.

News

Test could end uncertainty in inherited muscle diseases

A new study suggests long-read 'nanopore' sequencing could transform the diagnosis of inherited diseases and unlock new insights for drug discovery.

News

Wnt drug gives MSD first eye disease win after EyeBio deal

MSD's return to the ophthalmology field has been charged up with a positive phase 3 trial of Wnt-targeted remigromig in diabetic macular oedema.

Novo turns to Hengrui for another oral obesity drug

Mirum puts Hepcludex in its sights with hep D readout

AZ takes stake in Summit Therapeutics in $2bn deal

Roche culls myostatin candidate from obesity pipeline

Test could end uncertainty in inherited muscle diseases

Wnt drug gives MSD first eye disease win after EyeBio deal

AZ grabs FDA nod for Ultomiris in rare kidney disease IgAN

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks